AbbVie Dividend Yield Information for Investors

AbbVie is a well-established pharmaceutical company with a long history of paying dividends to its shareholders. The company has consistently paid dividends since 2013, with a current payout ratio of around 50%.

AbbVie's dividend yield is influenced by its share price and dividend payout per share. The company's dividend payout has increased over the years, with a 5-year average annual growth rate of 10.3%.

Discover more: Share Repurchase Yield

As you explore AbbVie's dividend yield, it's essential to understand the company's dividend history. AbbVie has a long-standing tradition of paying consistent dividends to its shareholders, with the first recorded dividend payment dating back to January 2013.

The dividend yield is a crucial metric for investors, indicating the ratio of the annual dividend payment to the stock's current price. AbbVie's dividend yield has varied over the years, but it has consistently provided a relatively stable source of income for shareholders.

In 2024, AbbVie paid a dividend of $1.640 per share on January 15, 2025. This payment was declared on October 30, 2024, and the record date was also January 15, 2025.

Additional reading: Bank of Nova Scotia Dividend Payment Dates

Here's a summary of AbbVie's dividend payments in 2024:

AbbVie's dividend payments have been steadily increasing over the years, providing a growing source of income for shareholders. In 2023, the company paid a dividend of $1.480 per share, and in 2022, it paid $1.410 per share.

AbbVie's dividend yield is influenced by various factors, including the company's financial performance and the overall market conditions. However, the company's commitment to paying consistent dividends has made it an attractive option for income-seeking investors.

Consider reading: Where Do Dividends Go in Cash Flow Statement

ABBV's payout ratio is quite high, with a staggering 215.8% payout ratio, which means its dividend payments are not well covered by earnings.

This high payout ratio can be a concern for investors, as it may indicate that the company is struggling to generate enough earnings to support its dividend payments.

ABBV's cash payout ratio, on the other hand, is a more reasonable 74.2%, which suggests that its dividend payments are covered by cash flows.

This is a positive sign for investors, as it indicates that the company has a stable source of funds to support its dividend payments.

ABBV's dividend payments have been stable over the past 10 years, which is a testament to the company's commitment to its shareholders.

This stability is a key factor to consider for investors looking for a reliable dividend-paying stock.

ABBV's dividend payments have actually increased over the past 10 years, which is a great sign for investors who value growing dividend income.

Recommended read: National Health Investors Stock Dividend

Abbvie's financial data is impressive. The company has a market capitalization of over $180 billion, making it one of the largest pharmaceutical companies in the world.

Abbvie's dividend yield is a key metric for investors, and it's currently around 3.5%. This means that for every dollar you invest in Abbvie, you can expect to earn around 3.5 cents in dividend payments each year.

Abbvie's dividend payout ratio is around 50%, which is relatively low compared to other pharmaceutical companies. This suggests that the company has a healthy balance sheet and is generating plenty of cash to pay its dividend.

Suggestion: 3 Dividend Stocks to Buy and Hold Forever

Abbvie's revenue has been steadily increasing over the past few years, with a compound annual growth rate (CAGR) of around 10%. This growth is driven by the company's strong portfolio of products, including Humira, which is one of the best-selling drugs in the world.

Abbvie's operating margin is around 30%, which is significantly higher than the industry average. This suggests that the company is highly efficient and able to maintain its pricing power in the market.

Abbvie is a multinational biopharmaceutical company based in the United States. It was spun off from Abbott Laboratories in 2013.

The company's headquarters is located in North Chicago, Illinois.